ConvEyXo
0725.874.259 · rovalta.com · 25/09/2026
ACTIVE
ConvEyXo
Financial year 2025 · Closed on 31/12/2025
Net result-1,6 M €-69,6 %over 1 year
Gross margin-45,2 k €+40,8 %over 1 year
Equity1,4 M €-53,1 %over 1 year
Workforce3,1 ETP+10,7 %over 1 year
Overview
Identity
Source · BCE/KBOConvEyXo is a Public limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi. It employs on average 3,1 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0725.874.259
- Incorporation
- 30/04/2019
- Legal form
- Public limited company
- Registered office
- Rue Clément Ader 10
6041 Charleroi · WallonieSee on map - Contributed capital
- 2 752 165,60 €
- Latest accounts
- 31/12/2025
- Average workforce
- 3,1 ETP
Activities (NACE)
72101Research and experimental development on natural sciences and engineering· main72110Research and experimental development on biotechnology72109Research and experimental development on natural sciences and engineering72190Other research and experimental development on natural sciences and engineering72200Research and experimental development on social sciences and humanities72200Research and experimental development on social sciences and humanities
Signals
Positive cashflowHealthy social debts
Financials
Source · NBB, 7 filingsTrend over 7 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -45,2 k € | +40.8% | -76,4 k € | +82.6% | -440,3 k € | -0.2% | -439,2 k € | -139% | -183,5 k € |
| EBITDA | -441,9 k € | -49.6% | -295,3 k € | +48.0% | -567,6 k € | -18.7% | -478 k € | -160% | -183,8 k € |
| Operating result | -2,1 M € | -42.9% | -1,5 M € | +2.7% | -1,5 M € | +11.2% | -1,7 M € | -55.6% | -1,1 M € |
| Net result | -1,6 M € | -69.6% | -946,7 k € | +13.0% | -1,1 M € | +22.9% | -1,4 M € | -72.7% | -817,8 k € |
| Balance sheet | |||||||||
| Equity | 1,4 M € | -53.1% | 3 M € | -0.9% | 3 M € | +65.0% | 1,8 M € | +217% | 571,6 k € |
| Total assets | 10,3 M € | +29.5% | 7,9 M € | +51.2% | 5,2 M € | +58.8% | 3,3 M € | +42.7% | 2,3 M € |
| Cash | 1,6 M € | +4.7% | 1,5 M € | +1712% | 84,8 k € | -96.0% | 2,1 M € | +124% | 937,9 k € |
| Debts | 8,9 M € | +78.6% | 5 M € | +121% | 2,2 M € | +50.7% | 1,5 M € | -14.4% | 1,7 M € |
| Other | |||||||||
| Workforce | 3,1 ETP | +10.7% | 2,8 ETP | +100% | 1,4 ETP | +40.0% | 1,0 ETP | – | |
Valuation
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20254 active · 19 ended
Active mandates
Ended mandates
Frédéric Tonglet
EndedEnded
Other companies at this address
Rue Clément Ader 10 6041 Charleroi| Company | CBE no. |
|---|---|
2 Bridge WL● Active | 1003.906.745 |
3D Fibroscreen● Active | 1022.772.354 |
AdipoPharma Belgique● Active | 1008.146.338 |
ATRYON BELGIUM● Active | 0751.698.530 |
| 0479.250.670 | |
CONVEYXO GROUP● Active | 1016.957.797 |
ELKEDONIA BELGIUM● Active | 1021.635.177 |
ENDO TOOLS THERAPEUTICS● Active | 0807.570.233 |
Enodia Therapeutics Belgium● Active | 1039.324.811 |
EU BIOTECH CAMPUS● Active | 0776.668.706 |
Exo-Harvest● Active | 0803.425.264 |
Hemastatx● Active | 1019.406.058 |
Immunofusion● Active | 0804.563.629 |
ImmunXperts● Active | 0552.755.587 |
INCHINN THERAPEUTICS● Active | 0799.914.755 |
INSTAR BELGIQUE● Active | 1039.395.085 |
KOKUMA● Active | 0799.078.377 |
LYS MEDICAL● Active | 0688.626.061 |
MILEUTIS● Active | 1011.400.984 |
Nexelis Europe● Active | 0744.498.061 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 29/07/2026 | 29/07/2025 | 16/07/2024 | 28/07/2023 | 30/08/2022 | 31/07/2021 |
| General meeting | 27/07/2026 | 30/06/2025 | 28/06/2024 | 21/06/2023 | 30/06/2022 | 07/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 7 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 27/07/2026 | 29/07/2026 | French | |
| Abridged model | 31/12/2024 | 30/06/2025 | 29/07/2025 | French | |
| Abridged model | 31/12/2023 | 28/06/2024 | 16/07/2024 | French | |
| Abridged model | 31/12/2022 | 21/06/2023 | 28/07/2023 | French | |
| Abridged model | 31/12/2021 | 30/06/2022 | 30/08/2022 | French | |
| Abridged model | 31/12/2020 | 07/05/2021 | 31/07/2021 | French | |
| Micro model | 31/12/2019 | 02/05/2020 | 27/11/2020 | French |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20254 active · 19 ended
Active mandates
Ended mandates
Frédéric Tonglet
EndedEnded
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Registered office20/11/2025SIEGE SOCIAL
- Capital / shares08/01/2025CAPITAL, ACTIONS
- Mandates22/10/2024DEMISSIONS, NOMINATIONS
- Mandates22/10/2024DEMISSIONS, NOMINATIONS
- Registered office16/04/2024SIEGE SOCIAL
- Capital / shares30/11/2023STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Capital / shares01/08/2023CAPITAL, ACTIONS
- Mandates14/07/2023DEMISSIONS, NOMINATIONS
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-1,6 M €↓
- 2024Annual accounts 2024-946,7 k €↑
- 2023Annual accounts 2023-1,1 M €↑
- 2022Annual accounts 2022-1,4 M €↓
- 2022Name changeConvEyXo
- 2021Annual accounts 2021-817,8 k €↓
- 2021Name changeParacrine Biologicals
- 2020Annual accounts 2020-616,1 k €↓
- 2019Annual accounts 2019-407,7 k €
- 30/04/2019IncorporationPublic limited company